Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
On April 15, 2008, administrators notified the company of an increase in interests in Ordinary share ADRs for specific individuals following the reinvestment of dividends paid on April 10, 2008. The transaction price was $43.84 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in ADR holdings via dividend reinvestment.
- Transaction Date: April 15, 2008 (Notification); April 10, 2008 (Dividend Payment).
- Price per ADR: $43.84.
- Individuals Involved: Dr. JP Garnier (1,098.72 ADRs) and Mr. D J Phelan (235.44 ADRs).
- Financial Data: No financial performance metrics are included in this specific filing.